Karnofsky performance status scale

2009 ◽  
Vol 29 (4) ◽  
pp. 147-148 ◽  
Author(s):  
Arthur H. Friendlander ◽  
Ronald L. Ettinger
Keyword(s):  
Karnofsky Performance Status ◽  
Performance Status ◽  
Karnofsky Performance Status Scale ◽  
Performance Status Scale

scholarly journals Do Patients with a Poor Karnofsky Performance Status Scale Profit from Tumour Volume Reduction?

2020 ◽  
Author(s):  
Melanie Barz ◽  
Julia Gerhardt ◽  
Stefanie Bette ◽  
A. Kaywan Aftahy ◽  
Thomas Huber ◽  
...  
Keyword(s):  
Surgical Resection ◽  
De Novo ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Methylation Status ◽  
Tumour Volume ◽  
Residual Tumour ◽  
Karnofsky Performance Status Scale ◽  
Irradiation Treatment ◽  
Performance Status Scale

Abstract Purpose: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤ 60%.Methods: We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤ 60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status.Results: 123 patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. 75 of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm3 (IR 15.0–56.5cm3) and 3.1 ± 23.8 cm3 (IR 0.2–15.0 cm3), respectively. The median KPSS was 60% (range 20–60%) preoperatively and 50% (range 0–80%) postoperatively. The median OS was 123 ± 220 days (IR 52–395 days). Age (p<0.001, HR: 1.045 [95% CI 1.022–1.068]), postoperative tumour volume (p=0.02, HR: 1.016 [95% CI 1.002–1.029]) and MGMT promotor status (p=0.016, HR: 0.473 [95% CI 0.257–0.871]) were statistically significant in multivariate analysis.Conclusion: Patients with a preoperative KPSS of ≤ 60% benefit from low postoperative residual tumour volumes. Age and MGMT-methylation status were also significant prognostic parameters in this patient cohort.

scholarly journals Gliomatose Cerebral: Caso Clínico e Revisão da Literatura

2017 ◽  
Author(s):  
Rui Ramos ◽  
Cristiano Antunes ◽  
Maria João Machado ◽  
Renata Marques ◽  
Tiago Gil Oliveira ◽  
...  
Keyword(s):  
Karnofsky Performance Status ◽  
Performance Status ◽  
Karnofsky Performance Status Scale ◽  
Performance Status Scale

Relatamos o caso de um doente com diagnóstico de gliomatose cerebral que após dois quadros de hipertensão intracraniana grave, iniciou quimioterapia paliativa e evoluiu de forma clínica e imagiologicamente satisfatória. Doente de 33 anos de idade, previamente autónomo (Karnofsky Performance Status Scale de 100 pontos) e sem antecedentes pessoais/familiares relevantes. É investigado com tomografia computorizada e ressonância magnética cerebral no contexto de crise convulsiva inaugural. É detetada uma lesão infiltrativa fronto-parietal direita com extensão parietal contralateral através do esplénio do corpo caloso. Foi submetido a biópsia lesional por neuronavegação com diagnóstico histológico de astrocitoma grau II (OMS). Perante a integração imagiológica e anatomopatológica define-se então um processo de gliomatose cerebral. Após alta hospitalar recorre por duas vezes ao serviço de urgência com quadro de hipertensão intracraniana grave, uma das quais em estado de coma e com anisocoria pupilar.Após internamento e corticoterapia endovenosa em altas doses, recupera neurologicamente para o seu estado basal. Vinte e sete meses após o diagnóstico, encontra-se assintomático, sem défices neurológicos focais e com estabilidade imagiológica da lesão tumoral. A gliomatose cerebral é uma neoplasia rara, de apresentação clínica variável e com um diagnóstico baseado nas características imagiológicas e histológicas. Após o início dos tratamentos complementares, nomeadamente quimioterapia, poderá ser possível uma estabilização clínica e imagiológica prolongada. Recebido: 10/10/2016 - Aceite: 05/09/2017

scholarly journals Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Melanie Barz ◽  
Julia Gerhardt ◽  
Stefanie Bette ◽  
A. Kaywan Aftahy ◽  
Thomas Huber ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Surgical Resection ◽  
De Novo ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Tumour Volume ◽  
Significant Prognostic Factor ◽  
Karnofsky Performance Status Scale ◽  
Irradiation Treatment ◽  
Performance Status Scale

Abstract Backround Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤60%. Methods We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status. Results One hundred twenty-three patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. Seventy-five of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm3 (IR 15.0–56.5cm3) and 3.1 ± 23.8 cm3 (IR 0.2–15.0 cm3), respectively. The median KPSS was 60% (range 20–60%) preoperatively and 50% (range 0–80%) postoperatively. Patients who received a biopsy showed a median OS for patients who received a biopsy only was 3.0 months (95% CI 2.0–4.0 months), compared to patients who had a resection and had a median OS of 8 months (95% CI 3.1–12.9 months). Age (p < 0.001, HR: 1.045 [95% CI 1.022–1.068]), postoperative tumour volume (p = 0.02, HR: 1.016 [95% CI 1.002–1.029]) and MGMT promotor status (p = 0.016, HR: 0.473 [95% CI 0.257–0.871]) were statistically significant in multivariate analysis. In subgroup analyses only age was shown as a significant prognostic factor in multivariate analyses for patients receiving surgery (p < 0.001, HR: 1.046 [95% CI 1.022–1.072]). In the biopsy group no significant prognostic factors were shown in multivariate analysis. Conclusion GBM patients with a preoperative KPSS of ≤60% might profit from surgical reduction of tumour burden.

Performance Status Assessment in Home Hospice Patients Using a Modified Form of the Karnofsky Performance Status Scale

2000 ◽  
Vol 3 (3) ◽  
pp. 301-311 ◽  
Author(s):  
Suzanne Nikoletti ◽  
Davina Porock ◽  
Linda J. Kristjanson ◽  
Krishna Medigovich ◽  
Pender Pedler ◽  
...  
Keyword(s):  
Karnofsky Performance Status ◽  
Performance Status ◽  
Karnofsky Performance Status Scale ◽  
Hospice Patients ◽  
Status Assessment ◽  
Performance Status Scale

Quality of Life After Brainstem Cavernoma Surgery in 71 Patients

Neurosurgery ◽  
2011 ◽  
Vol 69 (3) ◽  
pp. 689-695 ◽  
Author(s):  
Thomas Dukatz ◽  
Johannes Sarnthein ◽  
Helmut Sitter ◽  
Oliver Bozinov ◽  
Ludwig Benes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Health Survey ◽  
Short Form ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Karnofsky Performance Status Scale ◽  
Short Form 36 ◽  
Brainstem Cavernoma ◽  
Performance Status Scale

Abstract BACKGROUND: Symptomatic patients with a brainstem cavernoma are treated surgically with increasing frequency. Generally, the patient's benefit from this difficult surgical intervention is quantified by the assessment of neurological symptoms. OBJECTIVE: To document the beneficial effect of surgery in a larger patient population by assessing the postoperative quality of life (QoL). METHODS: In a series of 71 surgically treated patients, a detailed neurological status was assessed by Patzold Rating and Karnofsky Performance Status Scale. Patients rated their QoL with the Short Form 36 Health Survey. To document the effect of surgery on QoL, we devised a supplementary questionnaire. The last 24 patients completed Short Form 36 Health Survey pre- and postoperatively. RESULTS: Karnofsky Performance Status Scale improved in 44 of 71 surgical patients (62%), remained unchanged in 19 (27%), and deteriorated in 8 (11%) individuals. Patzold Rating showed a more detailed picture of the neurological symptoms. It correlated significantly with Karnofsky Performance Status Scale, which underscores its usefulness for patients with brainstem lesions. In the Short Form 36 Health Survey score, the Mental Component Summary improved with surgery (paired test, P = .015). In addition, 58 individuals (82%) declared a clear subjective benefit of surgery. CONCLUSION: The results of this large series support the notion that microsurgical removal of a brainstem cavernoma represents an effective therapy in experienced hands and is generally associated with good clinical outcome, both neurologically and in terms of QoL.

Sign in / Sign up

Export Citation Format

Share Document